Industry Briefs: January 14, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: January 14, 2013
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company News

Agensys, an affiliate of Astellas Pharma, has opened a new R&D facility in Santa Monica, California. The company’s current 250 employees and contractors will move to the new 160,000-ft2 facility during the next few months. At capacity, the buildings will hold just over 300 employees. Read More

Almac is expanding its drug-product pharmaceutical-development services with the creation of a new non-GMP formulation-development facility and two new analytical laboratories at its Craigavon, United Kingdom, headquarters. Read More

Biotest Pharmaceuticals has entered into a long-term manufacturing, supply, and license agreement with ADMA Biologics (ADMA). Under the agreement, ADMA has agreed to purchase exclusively from Biotest its worldwide requirements of respiratory syncytial virus immune globulin manufactured from human plasma containing RSV antibodies. The initial term of the agreement is for 10 years. Biotest will receive payment for manufacturing services provided under the agreement as well as a percentage royalty on ADMA’s product revenues up to a specified maximum. In exchange, Biotest has agreed to provide manufacturing services and granted ADMA a license to use Biotest’s proprietary fractionation and purification manufacturing process for intravenous immune globulin. Read More

Catalent Pharma Solutions plans to make a major investment to expand its inhalation drug-development, delivery, and supply capabilities by enhancing its Inhalation Center of Excellence in Research Triangle Park, North Carolina. The $20-million planned investment will focus on expanding pressurized metered dose inhaler clinical and commercial supply capabilities, as well as other enhancements to the facility. Read More

As of Jan. 1, 2013, the Eisai Machinery companies in Germany, China, and North America, were renamed to Bosch Inspection Technology following the acquisition of Eisai by Bosch in April 2012. In addition, Bosch Packaging Technology K.K. and its Japanese subsidiary Eisai Machinery Co. completed their merger into Bosch Packaging Technology K.K. Read More

Hamilton Storage Technologies has opened a new, 52,000-ft2 facility in Franklin, Massachusetts. The facility will serve as the sample management division’s headquarters and the East Coast competence center for Hamilton Company, a company that specializes in the design and manufacture of liquid-handling, process-measurement, robotics, and storage solutions. The facility, which will replace two separate facilities located in Hopkinton and Milford, Massachusetts, includes 30,000-ft2 of manufacturing space with a customizable, open-floor plan. Read More

Marken and BioStorage Technologies have formed a new partnership for the Singapore region that is intended to provide clients with full access to their biological samples at all times. Read More

In other news, Marken has opened a new, expanded pharmaceutical depot in Mexico City. Read More

People News

AMRI has named Richard A. Saffee vice-president and general manager of its large-scale manufacturing division. Read More

SCM Pharma has appointed Mark Edwards as quality assurance director to manage the company’s quality control function. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here